The extra benefit of using topical Clobetasol before Hydroquinone 4% in the treatment of Melasma

Phase 3

• Conditions: Melasma; C17.800

• Registration Number: RBR-4mzcwpw
• Lead Sponsor: niversidade Estadual Paulista (UNESP)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-12-28
• Last Update Posted: 29 May 2023
• Study Completion: 2023-12-01

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Women; age between 18 and 60 years old; with moderate to severe facial melasma or mMasi greater than 5; without treatment for at least 45 days except of the using of sunscreen

Exclusion Criteria

Pregnant and lactating women; carriers of other concomitant facial dermatoses; dermatoses with photosensitivity; glaucoma; previous episode of perioral dermatitis; melasma with mMASI less than 5; history of hypersensitivity or local adverse reactions to the use of hydroquinone or clobetasol or any other component of the formulation described

Study & Design

• Study Type: Intervention
• Study Design: Not specified